Biosimilars and the future of more affordable treatment for hematologic malignancies
EBMT 2017: Highlighting the hottest topics in the field of transplantation
Double hit lymphoma: a challenge for lymphoma experts
Better survival outcomes with the use of new CLL drugs
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?